CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Superluminal secures $60M for Phase 1 of genetic obesity drug

Phase 1Positive
AI Analysis

Summary

Superluminal Medicines secured $60 million in Series B funding to advance its MC4R-based genetic obesity drug into Phase 1 clinical testing, following competitors in the obesity treatment space.

Clinical Trial Data

Phase

Phase 1

Importance:6/10
Sentiment:
0.70
obesityMC4RSeries Bgenetic obesityPhase 1

Read the original article

Published by Endpoints News on September 3, 2026 10:00 AM

Read Original